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Background: The aim of this study was to identify novel candidate biomarker proteins differentially expressed
in the plasma of patients with early stage acute myocardial infarction (AMI) using SELDI-TOF-MS as a high
throughput screening technology.
Methods: Ten individuals with recent acute ischemic-type chest pain (b12 h duration) and ST-segment
elevation AMI (1STEMI) and after a second AMI (2STEMI) were selected. Blood samples were drawn at six
times after STEMI diagnosis. The ﬁrst stage (T0) was in Emergency Unit before receiving any medication, the
second was just after primary angioplasty (T2), and the next four stages occurred at 12 h intervals after T0.
Individuals (n=7) with similar risk factors for cardiovascular disease and normal ergometric test were selected
as a control group (CG). Plasma proteomic proﬁling analysis was performed using the top-down (i.e. intact
proteins) SELDI-TOF-MS, after processing in a Multiple Afﬁnity Removal Spin Cartridge System (Agilent).
Results: Compared with the CG, the 1STEMI group exhibited 510 differentially expressed protein peaks in the
ﬁrst 48 h after the AMI (pb0.05). The 2STEMI group, had ~85% fewer differently expressed protein peaks than
those without previous history of AMI (76, pb0.05). Among the 16 differentially-regulated protein peaks
common to both STEMI cohorts (compared with the CG at T0), 6 peaks were persistently down-regulated at
more than one time-stage, and also were inversed correlated with serum protein markers (cTnI, CK and CKMB)
during 48 h-period after IAM.
Conclusions: Proteomic analysis by SELDI-TOF-MS technology combinedwith bioinformatics tools demonstrated
differential expression during a 48 h time course suggests a potential role of someof these proteins as biomarkers
for the very early stages of AMI, as well as for monitoring early cardiac ischemic recovery.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Coronary artery disease (CAD) and acute myocardial infarction
(AMI) are major cause of morbidity and mortality worldwide. AMI
symptoms are frequently atypical or absent and alterations in the
electrocardiogram (ECG) are often unspeciﬁc or absent in acute
coronary syndromes (ACS). The human genome project has not yet
generated major improvements in the diagnosis and prognosis of
CAD, particularly in AMI, despite many technological advances. AMI
diagnosis has traditionally relied on symptoms, abnormalities in theo Grande do Norte, Pharmacy
, Av. General Cordeiro de Faria
er@ufrnet.br (V.N. Silbiger).
vier OA license.ECG, and subsequent elevation in serum proteins markers such as
myoblobin, creatine kinase (CK), CK-MB, troponin I (cTnI) and
troponin T (cTnT). However, symptoms like chest pain are frequently
atypical or absent and alterations in the ECG can be non-speciﬁc or
absent [1]. Furthermore, commonly used serum markers may be
altered in a number of non-cardiac problems, such as trauma,
seizures, renal insufﬁciency, hyperthermia, and hyperthyroidism,
and have low sensitivity (35% for CK-MB and cTnI) and speciﬁcity
(85 and 86% for CK-MB and cTnI, respectively) in the ﬁrst 8 to 10 h
after injury [2]. In addition, 10–20% of the patients with chest pain
do not have ACS [1]. Therefore earlier diagnosis of AMI may reduce
mortality and avoid unnecessary admissions to cardiac care units,
reducing medical costs [2].
The pathophysiology of AMI is complex with multi-factorial risks.
Evaluation of whole proteomic response in a high throughput system
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AMI [3]. The plasma contains thousands of proteins and peptides that
regulate a large number of physiologic functions and are involved in
pathological conditions [3]. Identiﬁcation of plasma protein proﬁles
that are involved in early events of AMImay improve its diagnosis and
prognosis.
Proteomics, the global study of proteins, is a powerful tool to
identify biomarkers and proteins involved in the pathogenesis of
speciﬁc diseases. High-throughput proteomic investigations can
provide a rich view of cellular processes and unique insights into
biological complexity through data-mining of the mountains of data
that these approaches produce to guide the development of new
diagnostics and therapies for human diseases [4].
Surface-Enhanced Laser Desorption/Deionization Time of Flight
Mass Spectrometry (SELDI-TOF-MS) allows identiﬁcation of a large
number of potential biomarkers in a biological sample, based on
molecular weights and chemical characteristics [5] and running a
large number of samples simultaneously in a relatively short period of
time [3]. It allows scanning a broad range of molecular weight (MW)
of proteins (500 Da to 100 kDa). It is highly sensitive (to 50 fmoles),
reproducible, reliable and requires minimal amounts of sample for
analysis [6]. SELDI-TOF-MS has been successfully used to discover
new biomarkers for many diseases, including cancers, rheumatoid
arthritis [7], infectious diseases [8,9], thromboembolism [3] and
autoimmune thyroid eye disease [10]. In this study, plasma proteomic
proﬁles of human AMI were analyzed by SELDI-TOF-MS over a pre-
determined time course to identify potential cardiac ischemia-related
biomarkers during the ﬁrst 48 h-period after AMI.
2. Subjects and methods
2.1. AMI patients
This study was approved by the Institutional Review Boards of the
relevant institutions, and written informed consents were obtained
from all participants. Ten individuals with ST-segment elevation AMI
(STEMI) admitted at the Emergency Unit of the Instituto Dante
Pazzanese de Cardiologia (Sao Paulo, SP, Brazil) were included. All
patients (between ages 36 and 65 years) were diagnosed with acute
ischemic-type chest pain of b12 h duration and an AMI by clinical and
ECG by WHO criteria [11]. The patient group included subjects who
had their ﬁrst STEMI (1STEMI; n=5) and those with a second
(2STEMI; n=5) within one year after their ﬁrst AMI. The control
group (CG) included individuals without AMI (n=7, aged 38 to
57 years), had similar risk factors for CAD [12] and normal ECG [13].
Systolic/diastolic blood pressures were measured in supine position
after resting for 30 min using a mercury column sphygmomanometer.
Individuals with systolic/diastolic blood pressure of N140/90 mmHg or
taking anti-hypertensive therapy were considered hypertensive [12].
Subjects with body mass index (BMI) higher than 30 kg/m2 were
classiﬁed as obese. Individuals with fasting glycemia N126 mg/dl
(7.0 mmol/l) or those receiving any hypoglycaemic medication were
considered diabetic; also those with increased total cholesterol
(N220 mg/dl; 5.7 mmol/l) or triglycerides (N200 mg/dl, 2.26 mmol/l),
or under lipid-lowering drugs treatmentwere considered dyslipidemic.
Smokers smoked at least 3 cigarettes a day at the time of the analysis,
ex-smokers had stopped at least 6 months and non-smokers had
never smoked [12]. A family history of CAD was considered as a ﬁrst-
degree relative with AMI before age of 55 years for men and 65 years
for women.
2STEMI individuals were taking multiple cardiac related medica-
tions (aspirin, clopidogrel, beta-blockers, diuretics, statins, nitrates,
anti-arrhythmics, angiotensin converting enzyme inhibitors, calcium
channel blockers and angiotensin II receptor blockers) consistent with
standard post AMImanagement [14], in addition to other medications
(non-steroidal anti-inﬂammatory drugs and proton pump inhibitors).Patients with instable angina, collagen vascular or peripheral
vascular disease, cardiomyopathy, pericardial disease, diabetes,
kidney or liver insufﬁciency, inﬂammatory disease, thyroid dysfunc-
tion, familial hypercholesterolemia, congenital diseases, hematologi-
cal diseases or cancer were excluded from the study.
2.2. Blood sampling and biochemical measurements
Blood samples were drawn from an antecubital vein using
vacutainer tubes (Becton Dickinson, Plymouth, UK) at six time points
(stages) after STEMI diagnosis. The ﬁrst stage (T0) was on admission
to the Emergency Unit prior to patients receiving any medication.
The second stage (T2) blood was obtained after angioplasty within
2 h after T0. Samples for the subsequent four stages were obtained at
12 h (T12), 24 h (T24), 36 h (T36) and 48 h (T48). For the CG, blood was
collected at one time point (T0).
Serum was used for biochemical determinations. Heparin-
anticoagulated plasma was immediately frozen at −80 °C until
proteomics analysis. Glucose, urea, creatinine, uric acid, total cholester-
ol, HDL cholesterol, and triglycerides were determined in serum by
routine enzymatic procedures using a fully automated system Hitachi
mod912 (RocheDiagnostic, São Paulo, Brazil). LDL andVLDL cholesterol
were calculated using the Friedewald formula when the triglycerides
concentration did not exceed 4.52 mmol/l. Serum cTnI was measured
using chemiluminescent assay (IMMULITE® Diagnostic Products
Corporation, Los Angeles, USA). CK-MB mass and CK were measured
by immunoassays and kinetics routine methods, respectively (Dimen-
sion® RXL, Dade Behring, Deerﬁeld, USA).
2.3. Immunoafﬁnity depletion of high-abundant protein from human
plasma
The Multiple Afﬁnity Removal Spin Cartridge System (Agilent
Technologies, Miami, USA) was used to remove more than 98% of the
most abundance proteins (albumin, IgM, IgG, IgA, haptoglobin,
transferrin, α1-antitrypsin, ﬁbrinogen, α2-macroglobulin, α1-acid
glycoprotein, apolipoprotein AI, apolipoprotein AII, complement C3
and transthyretin) according to manufacturer's instructions. Brieﬂy,
6 μl of human plasma was diluted 16-fold with Buffer A and ﬁltered
through a 0.22-μm spin ﬁlter (1 min, 14,000×g). The non-bound
protein fraction was collected and the columnwas washed twice with
Buffer A and centrifuged (2.5 min, 100×g). The bound fraction was
washed from the cartridge with 2.5 ml of Buffer B. The non-bound
protein fractions were pooled and concentrated with Nanosep 3 K
Omega Centrifugal Device (Pall Life Sciences, Port Washington,USA).
All plasma samples were processed in duplicates.
2.4. SELDI-TOF-MS
The immunodepleted plasma was applied in duplicate onto
Hydrophobic H50 ProteinChip arrays (Bio-Rad Laboratories, Hercules,
USA). H50 ProteinChip arrays were washed with 50% acetonitrile for
5 min then allowed to dry at least 30 min. When fully dry, 19 μl of
sample containing 9 M urea and 30 mg/ml of CHAPS and 180 μl of
Binding Buffer were applied to each spot of the ProteinChip and
incubated for 1 h. The spots were washed three times with 200 μl of
washing buffer for 5 min and rinsedwith distilledwater twice. Protein
chips were air-dried prior to the application of two 1 μl aliquots of the
energy absorbingmatrix (EAM) sinapinic acid (SPA, saturated solution
in 50% acetonitrile and 0.5% triﬂuoroacetic acid), with air-drying
between applications. The chips were analyzed in a Protein Reader
System PBS-IIC (PBS-IIC, Ciphergen Biosystems, Fremont, USA), which
was calibrated using the All-in-One Peptide Standard mass standard.
The laser shot intensity was set at 175, and sensitive at 9. The mass/
charge (m/z) spectra of protein range optimized for this study was
between 2 and 20 kDa, the m/z values are equivalent to the MW.
Table 1
Biochemical data and prevalence of risk factors for myocardial infarction in STEMI
groups and CG.
CG (7) 1STEMI (5) 2STEMI (5) p-value*
Age (y) 47.1±7.2 52.8±10.2 52.8±10.6 0.39
BMI (kg/m2) 25.8±2.5 26.4±5.0 26.2±2.6 0.95
Hypertension (%) 0.28 0.4 1 0.81
High LDL-c (%) 0.71 1 0.6 0.30
Family history of CAD (%) 0.57 0.8 0.8 0.60
Smoking (%) 1 1 0.8 0.59
Sedentary life style (%) 0.28 0.6 0.6 0.44
Total cholesterol (mmol/l) 5.5±1.2 5.3±1.1 4.8±0.7 0.60
HDL cholesterol (mmol/l) 1.1±0.4 0.8±0.1 0.8±0.1 0.09
LDL cholesterol (mmol/l) 3.5±1.1 3.7±1.0 3.1±0.6 0.70
VLDL cholesterol (mmol/l) 0.4±0.2 6.1±4.9 6.9±2.5 0.52
Triglycerides (mmol/l) 2.1±0.8 1.7±1.4 1.9±0.7 0.56
Glucose (mmol/l) 5.1±0.7 5.5±0.5 5.4±0.6 0.69
Number of individuals in parenthesis. Continuous variables are presented as mean±SD
and were compared by Kruskal–Wallis test. Categorical variables were compared by
chi-square test. CG: control group; 1STEMI: patient with ST-segment elevation acute
myocardial infarction without previously historic of heart ischemia; 2STEMI: patient
with ST-segment elevation acute myocardial infarction with previously historic of heart
ischemia; BMI: body mass index; CAD: coronary artery disease; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; TG: triglyceride; VLDL: very low-density
lipoprotein.
Individuals with BMI≥30 kg/m2 were classiﬁed as obese and those with systolic/
diastolic blood pressure≥140/90 mmHg or were under antihypertensive therapy were
considered hypertensive.
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A time-series background subtraction method was used for
background subtraction for minimal data bias. Data normalization
was accomplished by dividing the intensity of each peak by the total
ion current. A novel approach based on the Helmholtz principle
[15–18] was then used to ﬁnd peaks in the spectral data and to cluster
peaks [19]. Extracted features were then used for statistical analysis.
The Helmholtz principle is based on ﬁnding “meaningful” sections
of data, and a section of data is regarded as “meaningful” if the number
of false alarms compared with a random set of data is small. The false
alarm rate is computed using expectations to allow for a more robust
analysis, and the false alarm rate can be chosen to match user
requirements [20]. To ﬁnd peaks in spectral data, modes of spectral
data were ﬁrst determined, with amode being deﬁned as the intensity
signal increasing on the left hand side and decreasing on the right
hand side [15]. If the proﬁle is assumed to be a histogram, then a peak
is the mode of that histogram.
Each mode of the spectral data therefore corresponds to a protein
peak (i.e. a potential biomarker) and does not depend on an arbitrary
chosen threshold. This increases the reliability of the peak detection
method, and consequently the false alarm parameter has a physical
meaning. After ﬁnding peaks, the Helmholtz principle was used again
with a dendrogram [15] to provide powerful and novel clustering
algorithms to cluster peaks. Inmost clustering algorithms, an arbitrary
threshold is used to determine what constitute a cluster. This is a
global approach, and can identify points in a random pattern as a
cluster or merge clusters that are close together.
In the dendrogram method, clusters are represented by nodes of a
tree. Using the meaningful concept, the binomial distribution is used
to determine a false alarm rate that can be prescribed to each node
indicating whether that particular node cluster can occur by chance.
The use of the binomial distribution eliminates the arbitrary
parameter [15]. The trinomial distribution is then used to determine
if two closely spaced clusters should be merged, providing a robust
automated algorithm for cluster determination. This becomes impor-
tant when determining if a spectral peak height (i.e. signal intensity
which is a measure of a speciﬁc protein relative abundance) changes
as a result of inﬂammation or other factors.
After peak detection, the dataset was further reduced by only
considering peaks that are present in 90% of disease from STEMI
samples. This is to ensure that peaks to be used as features for
subsequent classiﬁcation scheme are robust and reliable, since if
peaks are not in 90% of the samples, noise would hide that particular
peak at least 10% of the time. The development of this analysis
algorithm for mass spectrometry data has been published [19].
2.6. Statistical analysis
Continuous variables are presented as mean±SD and were
compared by Kruskal–Wallis test and Mann–Whitney test. Categorical
variableswere comparedby chi-square test. Theareasunder the receiver
operator characteristic (ROC) curves for the candidate biomarkers
and their Spearman correlation with serum proteins markers (CK, CK-
MB, cTnI) were calculated by SPSS software v. 15 (SPSS, Illinois, USA).
P-values less than 0.05 were accepted as statistically signiﬁcant.
The background-adjusted and normalized data of protein peaks
intensities were analyzed using the R-statistics based BRB Array Tools
(version 3.7) [20]. Initial ﬁltering and sub-setting of the data based on
a 1.5-fold change from the median value, and a log intensity variation
of p-valueN0.01 gave 3844 peaks that passed the ﬁltering criteria, and
these were then used in subsequent statistical analysis. Statistical and
Venn-diagram analyses were carried out using Partek Genomics Suite
software v.6.3 (Partek, St. Louis, USA).
One-way analysis of variance and the univariate two-sample t-test
were used to compare peaks of proteins for each stage of STEMIgroups and CG. Because a large number of hypothesis tests in a small
sample size are performed in such variable-by-variable analyses,
many true-null hypotheses will produce small p-values by chance. As
a consequence, numerous false positives, or type I errors, will result if
p-values are compared to standard single-test thresholds [21]. There
are well-established procedures which address the multiple testing
problems in a reduced sample size by adjusting the p-values to control
various experiment-wide false positive measures [21], e.g. the False
Discovery Rate (FDR) method, based in Benjamini and Hochberg's
method [22,23]. Multiple testing adjustments for FDRwere performed
[22], forcing it to be FDR adjusted p-valueb0.05 and 1.5-fold change
[24], therefore allowing for a highly stringent analysis with no false
positive identiﬁcation of differentially regulated protein peaks.
3. Results
3.1. Clinical and biochemical evaluation of study subjects
The prevalence of risk factors for myocardial infarction in the STEMI
and CG groups are shown in Table 1. The mean age, BMI, and
biochemical variables were similar between the groups (p-valueN0.05).
Moreover, no differences were found in the number of individuals with
hypertension, dyslipidemia, cigarette smoking, familiar history of CAD,
and sedentary lifestyle between the groups (p-valueN0.05) (Table 1).
Serum concentrations of CK, CK-MB and cTnI are shown in Table
S1, values greater than the upper reference limit were found at T2.
Signiﬁcant increase of these biomarkers were detected only after
approximately 12 h post-1STEMI (p-valueb0.05), giving maximal
concentration values. No statistical difference was observed between
STEMI groups (p-valueN0.05).
4. Proteins differentially expressed
4.1. 1STEMI versus CG
The SELDI-TOF-MS spectra of the STEMI and CG samples were
plotted as a pseudo-gel view (data not shown) to allow overall
relative comparison of data quality. Based on this analysis, ﬁve of
the sixty-seven data samples were considered to be outliers and
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adjustment and data normalization, 3844 protein peaks passed the
ﬁltering criteria.
Five-hundred-ten proteins were differentially expressed between
1STEMI group and the CG. Analysis of the time course revealed
different expression of 53, 104, 329, 85, 102 and 156 proteins at T0, T2,
T12, T24, T36 and T48, respectively (p-valueb0.05).
Among 53 protein peaks at T0, 23 protein peaks were up-regulated
(m/z: 2128.0 to 6109.0 Da) while 30 protein peaks with higher MW
were down-regulated (m/z: 6362.5 to 17,807.5 Da; Fig. 1; Table S2).
Eleven protein peaks remain up-regulated at 1STEMI T48, but only 3
remain altered at all time points (m/z: 2128.0, 2150.0 and 2195.0 Da).
Eight protein peak were initially up-regulated (m/z: 2135.5, 2158.0,
2180.5, 2182.0, 21,83.5, 22,13.5, 4267.0 and 6109.0 Da). Seventeen
protein peaks remain down-regulated at 1STEMI T48, 11 remained
down-regulated at all time points (m/z: 9217.0, 14,494.0 and 17,888.0Fig. 1. Fold-change time proﬁling of ﬁfty-three protein peaks differently expressed at
1STEMI. Unique id: peak of proteins identiﬁcation; m/z: mass/charge; 1STEMI: patient
with ST-segment elevation acute myocardial infarction without previously historic of
heart ischemia; T0: ﬁrst stage of STEMI; T2: second stage of STEMI; T12: third stage
within 12 h after STEMI; T24: fourth stage within 24 h after STEMI; T36: ﬁfth stage
within 36 h after STEMI; T48: sixth stage within 48 h after STEMI; ,1.5 to 3.0-fold
change (up-regulated); , 3.1 to 6.0-fold change; , 6.1 to 9.0-fold change; ,
N9.0-fold-change; , -1.5 to–3.0-fold-change (down-regulated); , −3.1 to–6.0-fold
change; , −6.1 to–9.0-fold change; ,b−9.0-fold change; ., protein peak not
statistical signiﬁcant.to 17,807.5 Da). Two proteins were down-regulated just at T0 (m/z:
11,842.0 and 15,457.0 Da).4.2. 2STEMI versus CG
Seventy-six proteins were differentially expressed between
2STEMI group and the CG. Analysis of the time course revealed
different expression of 36, 27, 23, 4, 13 and 19 proteins at T0, T2, T12,
T24, T36 and T48, respectively (p-valueb0.05).
Among 36 protein peaks at T0, 2 protein peaks were up-regulated
(m/z: 3755.5 and 5432.5 Da) while 34 protein peaks with higher MW
were down-regulated (m/z: 6386.5 to 17,825.5 Da; Fig. 2; Table S3),
as observed at 1STEMI T0. The 2 protein peaks up-regulated were not
different at others stages of 2STEMI. Seven protein peaks remain
down-regulated at 2STEMI T48, one remained altered during all
time periods (m/z: 6482.5 Da). Thirteen protein peaks were down-
regulated only at T0 (m/z: 8653.0 to 17,825.5 Da).Fig. 2. Fold-change time proﬁling of thirty-six protein peaks differently expressed at
2STEMI T0. Unique id: peak of proteins identiﬁcation; m/z: mass/charge; 2STEMI:
patient with ST-segment elevation acute myocardial infarction with previously historic
of heart ischemia; T0: ﬁrst stage of STEMI; T2: second stage of STEMI; T12: third stage
within 12 h after STEMI; T24: fourth stage within 24 h after STEMI; T36: ﬁfth stage
within 36 h after STEMI; T48: sixth stage within 48 h after STEMI; ,1.5 to 3.0-fold
change (up-regulated); , 3.1 to 6.0-fold change; , 6.1 to 9.0-fold change; ,
N9.0-fold-change; ,−1.5 to−3.0-fold-change (down-regulated); ,−3.1 to−6.0-
fold change; ,−6.1 to−9.0-fold change; ,b−9.0-fold change; ., protein peak
not statistical signiﬁcant.
Fig. 3. Venn diagram analysis of protein peaks differently expressed in STEMI patients. A. Within the Venn diagram, the circles represent the union of the global protein peaks
resulted of our univariate two-sample t-test: each stage of 1STEMI versus control group (red circle) and each stage of 2STEMI versus control group (blue circle). B. The blue circle
represents the intersection of 1STEMI and 2STEMI and the others circles represent main effects of our t-test analysis: 1STEMI T0 (red circle) and 2STEMI T0 (green circle). Numbers
inside each compartment represent the number of proteins that are signiﬁcant. A false discovery rate adjusted p-values less than 0.05 and 1.5-fold change was accepted as
statistically signiﬁcant to identiﬁcation of differentially regulated protein peaks. 1STEMI: patient with ST-segment elevation acute myocardial infarction without previously historic
of heart ischemia; 2STEMI: patient with ST-segment elevation acute myocardial infarction with previously historic of heart ischemia and medication; T0: ﬁrst stage of STEMI; ∩:
intersection symbol.
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Sixty of 526 protein peaks were common to both STEMI cohorts
(Fig. 3A). Twenty of 36 protein peaks differently expressed at T0 ofFig. 4. Principal component analysis of CG, 1STEMI T0 and 2STEMI T0 samples using 16
differently expressed peaks. The ability of the protein signature to discriminate
between the two sample groups was indicate by wide separation between the CG
(green) and STEMI (1STEMI at red and 2STEMI at blue) sample clusters. The ﬁrst
principal component (PC1) accounted for 62.6% of the variation, PC2 accounted for
14.6% of the variation, and PC3 accounted for 6.48% of the variation. The spheres
represent the samples graphic distribution. CG: control group; 1STEMI: patient with ST-
segment elevation acute myocardial infarction without previously historic of heart
ischemia; 2STEMI: patient with ST-segment elevation acute myocardial infarction with
previously historic of heart ischemia; T0: ﬁrst stage of STEMI.2STEMI were not seen at T0 of 1STEMI, but were present at others
stages of 1STEMI; 36 of 53 proteins peaks at T0 of 1STEMI were unique
to that stage (Fig. 3B). The 16 protein peaks shared by both groups at
stage T0 were differently expressed in both groups. The PCA mapping
of theses protein peaks discriminated the STEMI groups from CG
yielding well-separated clusters (Fig. 4).
Among these 16 protein peaks, 3 were down-regulated in both
STEMI groups at T48 (m/z: 8437.0, 9217.0 and 9226.0 Da; Fig. 5; Table
S4). Interestingly, the expression proﬁle of these proteins was
inversely correlated with serum proteins markers (CK, CK-MB, cTnI;
r≤−0.30, p-valueb0.05), as shown in Table 2. In addition, the 3
protein peaks were also down-regulated at more than one stage (m/z:
10,757.5, 17,788.0 and 17,798.5 Da) and showed a statistical inverse
correlation with cTnI and CK (r≤−0.26, p-valueb0.05). Peak
intensity of another 5 protein peaks were positively correlated with
serum concentration proﬁle of cTnI (m/z: 17,788.0 to 17,807.5 Da;
r≤−0.26, p-valueb0.05).5. Discussion
Rapid diagnosis in the Emergency Unit is essential to guide ACS
treatment. Decisions on acute invasive procedures (angioplasty, stent
angioplasty, etc.) for an AMI are usually based on ECG changes (ST
segment elevations) and must be made before cardiac enzymes are
increased in the blood. However, many patients with AMI (non-ST
segment elevation AMI, left bundle branch block, etc.) do not have
ECG changes that allow early diagnosis. Therefore, acute invasive
procedures that are most effective in the ﬁrst few hours after an AMI
for preventing heart muscle damage are not initiated in these patients
and when the ﬁnal diagnosis is made several hours later, it is too late
for an acute invasive intervention. Protein biomarkers released in the
very early stages of an AMI that could be identiﬁed and developed as
rapid diagnostic tests would allow earlier treatment of these patients
and decrease the myocardial damage that results from delay of acute
invasive procedures. This pilot study identiﬁed potential early, new
AMI biomarkers in a high throughput SELDI-TOF-MS system,
combined with advanced data mining algorithms. These potential
biomarkers, as with other biomarkers, must be identiﬁed, objectively
Fig. 5. Fold-change time proﬁling of the sixteen protein peaks differently expressed for both STEMI groups. Unique id: peak of proteins identiﬁcation; m/z: mass/charge; 1STEMI:
patient with ST-segment elevation acute myocardial infarctionwithout previously historic of heart ischemia; 2STEMI: patient with ST-segment elevation acutemyocardial infarction
with previously historic of heart ischemia; T0: ﬁrst stage of STEMI; T2: second stage of STEMI; T12: third stage within 12 h after STEMI; T24: fourth stage within 24 h after STEMI; T36:
ﬁfth stage within 36 h after STEMI; T48: sixth stage within 48 h after STEMI; N9.0-fold-change; ,−1.5 to−3.0-fold-change (down-regulated); ,−3.1 to−6.0-fold change; ,
−6.1 to −9.0-fold change; ,b−9.0-fold change; ., protein peak not statistical signiﬁcant.
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pathogenic processes or pharmacological responses to therapeutic
interventions [25]. Biomarkers can be indicators of underlying
metabolic or pathophysiology aspects of disease, or provide a
reﬂection of substance exposure or intervention [26], or reﬂection of
the disease stage or event, such as an AMI, a consequence of CAD.
The ideal biochemical marker should be in high concentration in the
myocardium, absent in non-cardiac tissue, released rapidly in a linear
fashion following myocardial necrosis, and present in the circulation
long enough to be easily detectable by a relatively inexpensive and
widely available assay [36]. Troponin is still the preferred marker for
the detection of myocardial necrosis due to its tissue speciﬁcity
and established usefulness for therapeutic decision making [37]. It is aTable 2
Correlation coefﬁcients of serum proteins markers (cTnI, CK and CK-MB) and sixteen
protein peaks in the studied samples.
Unique
id (m/z)
cTnI CK CK-MB
r p-value r p-value r p-value
6386.5 −0.031 0.802 −0.127 0.305 0.048 0.701
6394.0 −0.041 0.744 −0.153 0.217 0.041 0.743
8437.0 −0.328 0.007 −0.358 0.003 −0.241 0.049
9217.0 −0.389 0.001 −0.405 0.001 −0.281 0.021
9226.0 −0.353 0.003 −0.363 0.003 −0.246 0.045
10,547.5 −0.028 0.824 −0.137 0.269 0.027 0.826
10,757.5 −0.259 0.034 −0.256 0.036 −0.080 0.522
10,760.5 −0.194 0.116 −0.162 0.191 0.015 0.906
15,446.5 0.026 0.836 0.016 0.899 0.173 0.162
17,788.0 −0.308 0.011 −0.232 0.059 −0.149 0.229
17,792.5 −0.312 0.010 −0.264 0.031 −0.176 0.153
17,797.0 −0.334 0.006 −0.279 0.022 −0.185 0.134
17,803.0 −0.293 0.016 −0.282 0.021 −0.175 0.157
17,804.5 −0.271 0.026 −0.259 0.035 −0.153 0.217
17,806.0 −0.267 0.029 −0.261 0.033 −0.145 0.243
17,807.5 −0.260 0.034 −0.266 0.030 −0.138 0.265
Correlations and p-value for Spearman correlation coefﬁcient.
Unique id: peak of proteins identiﬁcation; m/z: mass/charge; CK: creatine kinase;
CK-MB, creatine kinase isoenzyme MB; cTnI, troponin I.high MW protein (cTnI MW 24,008.0 Da; cTnT MW 35,924.0 Da,
UniProtKB database) released from myocytes when irreversible
myocardial damage occurs. It is highly speciﬁc to cardiac tissue and
accurately diagnoses myocardial infarction with a history of ischemic
pain or ECG changes reﬂecting ischaemia [38]. Unfortunately, an
important limitation of prior generation assayswas their low sensitivity
within theﬁrst hoursof AMI [37,38] asobserved at this study the current
generation troponin assays detect this serummarker only at T2 (almost
b12 h after symptom onset). In this study the time proﬁling approach
focus onprotein peaks identiﬁed in theﬁrst hours post-AMI at T0, before
the rise of the standard clinical AMI markers, cTnI, CK-MB and CK,
but also present more than one stage of the time-course evaluated
and correlated with this serum protein markers studied reﬂecting the
biologic involvement with myocardium ischemia.
Proteomics and bioinformatics are powerful tools to identify
protein biomarkers involved in disease pathogenesis. SELDI-TOF-MS
is useful for studies of a variety of clinical samples (including serum)
and even cell lines [27]. It has been used as a tool for initial
identiﬁcation of speciﬁc markers of diseases and to ﬁnd pathway in
certain physiological conditions because of its high sensitivity [2].
SELDI-TOF-MS, also known as protein proﬁle imprinting, is a novel
proteomic approach ﬁrst developed by Hutchens and Yip [27]. It is
an effective comparative proteomic approach that combines
both chromatography and mass spectrometry and offers several
advantages over traditional separation and identiﬁcation techniques
[28]. A large array of proteins can be rapidly processed, making SELDI-
TOF-MS a good method for high throughput screening of biomarkers,
particularly when the target protein is present in low abundance,
avoiding the limitations of antibody binding and focusing on a set of
predetermined proteins [6].
SELDI-TOF-MS had been widely used to study cardiovascular
disease. Delbosc et al. identiﬁed four original biomarkers directly
linked to L-NAME-induced hypertension in rat [29]. Zhang et al.,
studied serum sample of rats after ligation of their left anterior
descending coronary artery [30] at 5, 15, 30, 60, 120, 240 and 360 min
and found three peaks with m/z 7586, 7564 and 9583 Da which were
only present in the study groups [31]. Melle et al. applied SELDI-TOF-
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in the remodeled rat myocardium [32]. Blanco-Colio et al. identiﬁed
an 18.4 kDa protein peak as a potential diagnostic biomarker for
subclinical atherosclerosis [33]. Florian-Kujawski et al. reported that a
cluster of unique peaks between 10 and 12 kDa by SELDI-TOF-MS
with a strong anion exchange ProteinChip that were speciﬁc to
the patients with ACS [34]. However, SELDI-TOF-MS has not been
previously reported as used for a human plasma proteomic study for
discovery of a new biomarker during the very early stages of AMI.
In this study,we used SELDI-TOF-MSwithH50 ProteinChip arrays to
examine the temporal plasma proteomic proﬁle of the ﬁrst 48 h in
patientswith AMI and acute ischemic-type chest pain ofb12 hduration.
We studied two groups of AMI patients; one group of patients with
their ﬁrst AMI and another group with their second AMI on multiple
medications (e.g. aspirin, clopidogrel, beta-blockers, diuretics, statin,
nitrates, anti-arrhythmics, angiotensin converting enzyme inhibitor,
proton pump inhibitor, non-steroidal anti-inﬂammatory drugs, calcium
channel blockers and angiotensin II receptor blockers) [14].
Initial 1STEMI patients (no previous medication or intervention)
had 53 peaks that differentiated them from CG subjects with high
sensitivity and speciﬁcity (ranged from 87 to 99%). The 36 protein
peaks found at the ﬁrst stage of 2STEMI patients also differentiated
them from CG subjects with high sensitivity and speciﬁcity (86 to
100%). All up-regulated protein peaks were smaller MW proteins
(m/z: 2128 to 6109 Da at 1STEMI; 3755.5 and 5432.5 Da at 2STEMI)
and down-regulated proteins were larger (m/z: 6362.5 to 17,825.5 Da
at 1STEMI; 6386.5 to 17,825.5 Da at 2STEMI), possibly because
small proteins and/or peptides are more rapidly released upon tissue
damage (including cardiomyocyte apoptosis) than higher MW
proteins. In addition, exosomes containing inactive forms of mRNA,
microRNA, proteins and peptides can be released into the blood
from tissue injury [30,35]. The up-regulated proteins found in 1STEMI
T0 patients were not signiﬁcantly increased in the 2STEMI, but the
two up-regulated protein peaks found in 2STEMI T0 present at others
stages of 1STEMI, possibly due to previous treatments rendered after
their ﬁrst AMI or medications they were taking when they had their
second AMI.
Although our study compared both groups (1STEMI versus 2STEMI)
using the same stage (T0), the 2STEMI cohort underwent one
angioplasty procedure and pharmacological treatment before T0. The
pharmacological intervention may be responsible for the fold-change
proﬁles modiﬁcation between the STEMI groups. The revascularization
using stent and pharmacological treatment might change the dynamic
of response in the inﬂammatory response and an injury changing the
kinetic of protein proﬁle delivery in the circulation. We observed ~85%
fewer differentially expressed protein peaks in the 2STEMI group (76)
compared with the 1STEMI group (510), with maximum differentially
expressed protein values at T12 and T2 at the 1STEMI and 2STEMI,
respectively. This may be due, at least in part, to the differences in acute
angioplasties in the two groups at T2.
All protein peaks found at the ﬁrst stage of 2STEMI were also
present in 1STEMI patients, with 16 peaks observed at the same stage
(T0) and another 20 peaks after revascularization and medication
(including the two up-regulated proteins). The 16 protein peaks
present at the ﬁrst stage for both STEMI group were down-regulated
and identiﬁed the AMI with high sensitivity and speciﬁcity (90 to
98%; Table S4). They can be considered potential biomarkers for
early AMI independent of the inherent variability between our
STEMI patient groups. Interestingly, among this 16 protein peaks, 6
peaks were persistently down-regulated during the 48 h-period
after AMI, and were correlated with serum concentration time-
proﬁle of cTnI, CK and CK-MB markers (m/z: 8437, 9217, 9226,
10,757.5, 17,788 and 17,798.5 Da). These 6 protein peaks should be
studied further as potential biomarkers for early AMI. Larger patient
numbers and groups should be studied for validation of these
potential biomarkers, and the identity and function of these proteinselucidated. Diagnostic tests could then be developed and validated in
large population sizes.
One potential drawback of the present study was its relatively
small sample size, although our study is a longitudinal evaluation of
the study cohort. To reduce type I error, we have used stringent patient
stratiﬁcation criteria to minimize confounding factors, and ensuring
that all statistical analysis were performed with high cut-off
parameters, high fold change values and corrected for false discoveries
in multiple testings using the Benjamini and Hochberg's method. The
design of the present study was to investigate the proﬁle of time-
related changes in plasma protein markers for assessing the most
appropriate single time point to be used for biomarker measurement
in follow-up studies using larger sample numbers. Prior to validation
of discovered candidate biomarkers, the putative biomarkers will
have to be ﬁrst identiﬁed, and a simpliﬁed assay developed for the
target proteins. Chosen candidate biomarkers can then be validated
against large patient population to assess their utility as biomarkers
for AMI. These will be the basis of our follow-up studies towards
identifying AMI biomarkers. The present study, however, demonstrated
that SELDI-TOF-MS based proteomic proﬁling of plasma samples is a
powerful method for discovering very early biomarkers of AMI and
other ACS.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.cca.2011.02.030.
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